Market Overview:
The global fibromyalgia drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of fibromyalgia, rising awareness about the condition, and technological advancements in the field of fibromyalgia drugs. The global fibromyalgia drugs market is segmented on the basis of type into serotonin norepinephrine reuptake inhibitors (SNRIs), GABA analogs, and other types. The SNRI segment is expected to account for a major share of the global Fibromyalgia Drugs Market in 2018 owing to their high efficacy in treating symptoms associated with fibromyalgia.
Product Definition:
Fibromyalgia drugs are prescribed to help relieve the symptoms of fibromyalgia, a condition that causes pain and stiffness in the muscles and ligaments. The drugs may also help improve sleep quality and reduce fatigue.
Serotonin Norepinephrine Reuptake Inhibitors:
SSNRI's market is expected to grow at a rapid rate due to the increasing prevalence of diseases such as anxiety disorder, depression, and Parkinson's disease. The main factor that propels the growth of this market is its efficiency in treating disorders associated with serotonin norepinephrine reuptake inhibitors.
U.S SSNRI Market by Type (Major Drugs Class), 2012 - 2022 -> The U.
GABA Analogs:
GABA (GABAA) receptor-related ligands are the protein molecules that bind to the GABAA (subtype A) receptors. The binding of these ligands to their respective receptors causes inhibitory effects on the transmission of signals from nerve cells in the brain and spinal cord to muscles, glands, and organs.
U.S. Fibromyalgia Drug Market by Type/Formulation 2015 - 2022 -> The U.
Application Insights:
Based on application, the global market is segmented into hospitals, clinics and other. Hospitals held the largest share of over 70% in 2017. Fibromyalgia patients visiting hospitals for pain management are potential targets for drug advertisements and promotions. This factor is anticipated to boost hospital-based sales during the forecast period.
Clinics held a significant share in 2017 owing to increasing awareness about fibromyalgia among doctors and patients as well as growing availability of treatment options at relatively lower costs compared with hospitalization or surgery procedures. Moreover, these types of facilities have become popular alternatives for chronic pain patients who are uncomfortable with medical procedures or medications due to their religious beliefs or preferences regarding lifestyle modifications required by such treatments (such as dietary restrictions). These factors are expected to drive clinic-based revenue growth during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors responsible for its growth. In addition, a rise in awareness about fibromyalgia treatment options is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in R&D activities by major companies for developing novel drugs targeting specific symptoms associated with FM is also likely to support region’s growth over the next eight years.
Growth Factors:
- Increasing prevalence of fibromyalgia across the globe is expected to drive the growth of fibromyalgia drugs market over the forecast period.
- Rising awareness about fibromyalgia and its treatment options is anticipated to fuel the demand for fibromyalgia drugs in near future.
- Growing research and development activities for novel therapeutics for treating Fibromyalgia is likely to create new opportunities for players operating in this market during forecast period.
- Availability of government funding and initiatives towards research on Fibromyalgia is projected to propel the growth of this market in forthcoming years
Scope Of The Report
Report Attributes
Report Details
Report Title
Fibromyalgia Drugs Market Research Report
By Type
Serotonin Norepinephrine Reuptake Inhibitors, GABA Analogs, Other
By Application
Hospitals, Clinics, Other
By Companies
Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, Innovative Med Concepts, Meda, Meiji Seika, Switch Biotech, Theravance, Zynerba Pharmaceuticals, Tonix Pharmaceuticals Holding Corp. (TNXP)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
224
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Fibromyalgia Drugs Market Report Segments:
The global Fibromyalgia Drugs market is segmented on the basis of:
Types
Serotonin Norepinephrine Reuptake Inhibitors, GABA Analogs, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Eli Lilly
- Actavis
- Merck Sharp and Dohme
- Daiichi Sankyo
- Innovative Med Concepts
- Meda
- Meiji Seika
- Switch Biotech
- Theravance
- Zynerba Pharmaceuticals
- Tonix Pharmaceuticals Holding Corp. (TNXP)
Highlights of The Fibromyalgia Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Serotonin Norepinephrine Reuptake Inhibitors
- GABA Analogs
- Other
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fibromyalgia Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fibromyalgia drugs are medications used to treat fibromyalgia. Fibromyalgia is a condition that causes widespread pain in the muscles and joints. Drugs used to treat fibromyalgia may help reduce the pain and improve your quality of life.
Some of the major companies in the fibromyalgia drugs market are Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, Innovative Med Concepts, Meda, Meiji Seika, Switch Biotech, Theravance, Zynerba Pharmaceuticals, Tonix Pharmaceuticals Holding Corp. (TNXP).
The fibromyalgia drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fibromyalgia Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fibromyalgia Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fibromyalgia Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fibromyalgia Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fibromyalgia Drugs Market Size & Forecast, 2020-2028
4.5.1 Fibromyalgia Drugs Market Size and Y-o-Y Growth
4.5.2 Fibromyalgia Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Serotonin Norepinephrine Reuptake Inhibitors
5.2.2 GABA Analogs
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fibromyalgia Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fibromyalgia Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Serotonin Norepinephrine Reuptake Inhibitors
9.6.2 GABA Analogs
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Serotonin Norepinephrine Reuptake Inhibitors
10.6.2 GABA Analogs
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Serotonin Norepinephrine Reuptake Inhibitors
11.6.2 GABA Analogs
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Serotonin Norepinephrine Reuptake Inhibitors
12.6.2 GABA Analogs
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Serotonin Norepinephrine Reuptake Inhibitors
13.6.2 GABA Analogs
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fibromyalgia Drugs Market: Competitive Dashboard
14.2 Global Fibromyalgia Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Eli Lilly
14.3.3 Actavis
14.3.4 Merck Sharp and Dohme
14.3.5 Daiichi Sankyo
14.3.6 Innovative Med Concepts
14.3.7 Meda
14.3.8 Meiji Seika
14.3.9 Switch Biotech
14.3.10 Theravance
14.3.11 Zynerba Pharmaceuticals
14.3.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
